Work

Long lasting response to the combination of Avutometinib and Defactinib after progression on Binimetinib in a patient with recurrent low grade serous ovarian carcinoma − A case report

Year: 2025

Type: article

Abstract: Background: Treatment of recurrent chemotherapy, aromatase (AI) and MEK Inhibitor (MEKi) resistant low grade serous ovarian cancer (LGSOC) remains a challenge. Novel treatment options for KRAS mutated MEKi resistant LGSOC are warranted. Case: A 73-year-old with recurrent, metastatic, platinum-resistant LGSOC harboring a KRAS mutation experienced a prolonged response to the combination of Avutometinib and Defactinib after failing multiple lines of chemotherapy, aromatase inhibitor (AI), and targeted therapy with the MEK inhibitor Binimetinib (MEK-162). Following Avutometinib and Defactinib treatment, she experienced a confirmed and long-lasting (4 years) partial response as well as a return of CA-125 to baseline. The oral drug combination was well tolerated with no dose-limiting toxicity or need for dose reduction over the 4 year period. Conclusion: The Avutometinib and Defactinib combination may represent a new standard treatment option for platinum-resistant and AI-resistant/recurrent LGSOC who have failed other MEKi.

Source: Gynecologic Oncology Reports

DOI: 10.1016/j.gore.2025.102011

Authors: Victoria M. Ettorre, Luca Palmieri, Sarah Ottum, Michelle Greenman, Alessandro D. Santin

Institutions: Yale University, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $930